Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer owned 16,666 shares of the company’s stock, valued at $692,638.96. This trade represents a 41.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Wednesday, November 26th, Eben Tessari sold 200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $42.89, for a total value of $8,578.00.
• On Monday, November 17th, Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.24, for a total transaction of $514,262.80.
• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $37.67, for a total transaction of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $38.33, for a total transaction of $1,609,860.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA traded up $0.10 during midday trading on Wednesday, hitting $41.47. The company’s stock had a trading volume of 389,886 shares, compared to its average volume of 600,411. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The firm’s fifty day moving average price is $39.97 and its 200-day moving average price is $34.74. The firm has a market cap of $3.14 billion, a P/E ratio of 92.16 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same quarter last year, the company earned ($0.18) EPS. Kiniksa Pharmaceuticals International’s revenue was up 61.2% compared to the same quarter last year. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. TD Cowen began coverage on Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a “buy” rating and a $60.00 target price on the stock. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth $33,000. Vanguard Group Inc. grew its position in Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after buying an additional 151,604 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Kiniksa Pharmaceuticals International by 34.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 164,372 shares of the company’s stock valued at $3,651,000 after buying an additional 42,353 shares in the last quarter. Invesco Ltd. increased its stake in Kiniksa Pharmaceuticals International by 137.4% during the 1st quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock valued at $744,000 after buying an additional 19,384 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $16,992,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.